Skip to main content

Table 2 Univariate analyses of TGFBI methylation in non-small cell lung cancer patients

From: Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR

Variable

Methylation status

P-value

 

Absent

Present

 

Age (mean ± SD)

57.5 ± 8.4

60.0 ± 8.2

0.3037

Sex

  

0.4900

   Male

26 (56.5%)

20 (43.5%)

 

   Female

1 (25.0%)

3 (75.0%)

 

Pathological stage

  

0.8766

   I

9 (50.0%)

9 (50.0%)

 

   II

6 (50.0%)

6 (50.0%)

 

   III

10 (62.5%)

6 (37.5%)

 

   IV

2 (50.0%)

2 (50.0%)

 

Differentiation

  

0.3890

   Well

1 (50.0%)

1 (50.0%)

 

   Moderate

15 (48.4%)

16 (51.6%)

 

   Poor

8 (57.1%)

6 (42.9%)

 

   Unknown

3 (100.0%)

0 (0.0%)

 

Tumor size (cm) (mean ± SD)

4.19 ± 2.34

4.62 ± 2.62

0.6543

Tumor status

  

0.2946

   T1

11 (61.1%)

7 (38.9%)

 

   T2

12 (46.2%)

14 (53.8%)

 

   T3

2 (66.7%)

1 (33.3%)

 

   T4

1 (100.0%)

0 (0.0%)

 

   Tx

2 (100.0%)

0 (0.0%)

 

Metastatic status

  

0.6871

   Primary tumor

22 (61.1%)

14 (38.9%)

 

   Lymph node metastasis

4 (40.0%)

6 (60.0%)

 

   Distant metastasis

2 (50.0%)

2 (50.0%)

 

Histology

  

0.6614

   Adenocarcinoma

14 (58.3%)

10 (41.7%)

 

   Squamous cell carcinoma

12 (52.2%)

11 (47.8%)

Â